Holen Sie sich die Stockscreener-App
14.66
6.62%
0.91
Vorhandelsmarkt:
14.99
0.33
+2.25%
Schlusskurs vom Vortag:
$13.75
Offen:
$14.2
24-Stunden-Volumen:
107.81K
Relative Volume:
3.14
Marktkapitalisierung:
$2.52B
Einnahmen:
$603.63M
Nettoeinkommen (Verlust:
$468.71M
KGV:
5.4661
EPS:
2.682
Netto-Cashflow:
$-59.92M
1W Leistung:
+9.98%
1M Leistung:
+3.09%
6M Leistung:
-4.93%
1J Leistung:
-3.36%
1-Tages-Spanne:
$14.18
$15.00
1-Wochen-Bereich:
$13.20
$15.00
52-Wochen-Spanne:
$11.51
$19.50
Hutchmed China Limited Adr Stock (HCM) Company Profile
Vergleichen Sie HCM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HCM
Hutchmed China Limited Adr
|
14.66 | 2.36B | 603.63M | 468.71M | -59.92M | 2.682 |
|
ZTS
Zoetis Inc
|
125.67 | 57.00B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.90 | 49.88B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.05 | 45.73B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.40 | 36.84B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
RGC
Regencell Bioscience Holdings Ltd
|
52.88 | 16.33B | 0 | -5.87M | -767.30K | -0.45 |
Hutchmed China Limited Adr Stock (HCM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-22 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2025-05-13 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-11-24 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-05-04 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-09-22 | Herabstufung | Goldman | Buy → Neutral |
| 2021-08-03 | Eingeleitet | Jefferies | Buy |
| 2020-10-02 | Eingeleitet | Deutsche Bank | Buy |
| 2020-03-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-02-20 | Eingeleitet | Goldman | Buy |
| 2019-11-19 | Eingeleitet | CLSA | Buy |
| 2019-10-23 | Bestätigt | BofA/Merrill | Buy |
| 2019-07-05 | Eingeleitet | Macquarie | Outperform |
Alle ansehen
Hutchmed China Limited Adr Aktie (HCM) Neueste Nachrichten
Wall Street Analysts Predict a 55.93% Upside in HUTCHMED (HCM): Here's What You Should Know - Finviz
HUTCHMED (NASDAQ:HCM) Trading 8.1% HigherHere's What Happened - MarketBeat
HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China - GlobeNewswire Inc.
HUTCHMED (LON:HCM) Share Price Passes Below 200-Day Moving Average – Here’s What Happened - Defense World
HUTCHMED (NASDAQ:HCM) Sees Strong Trading Volume – Should You Buy? - Defense World
MACD Signals Flash Warning for The Hindustan Housing Company Limited StockMarket Entry Points & Free Navigate Market With Precision - bollywoodhelpline.com
HUTCHMED (NASDAQ:HCM) Sees Large Volume IncreaseShould You Buy? - MarketBeat
[6-K] HUTCHMED (China) Ltd Current Report (Foreign Issuer) | HCM SEC FilingForm 6-K - Stock Titan
REGHutchmed China LtdBlocklisting Six Monthly Return - TradingView — Track All Markets
HUTCHMED (NASDAQ:HCM) Sees Strong Trading VolumeTime to Buy? - MarketBeat
Brokerages Set HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Target Price at $20.88 - Defense World
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
HUTCHMED Initiates Global Clinical Development of ATTC Candidate HMPL-A251 in Patients with Solid Tumors - GlobeNewswire
Bearish block trade of HUTCHMED(00013) 278.5K shares at $22.0, $6.127M turnover - AASTOCKS.com
Schroder Investment Management Group Has $38.82 Million Stock Holdings in HUTCHMED (China) Limited Sponsored ADR $HCM - MarketBeat
HUTCHMED Share Movement in the (LSE:HCM) Landscape and FTSE Aim 100 - Kalkine Media
Forge Global Holdings, Inc. (NYSE:FRGE) Receives $42.00 Average Price Target from Analysts - Defense World
Rep. Lisa C. McClain Sells Off Shares of Gartner, Inc. (NYSE:IT) - Defense World
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Catalyst Funds Management Pty Ltd Sells 29,903 Shares of HUTCHMED (China) Limited Sponsored ADR $HCM - MarketBeat
ABN Amro Investment Solutions Invests $962,000 in HUTCHMED (China) Limited Sponsored ADR $HCM - MarketBeat
HMPL-A251 combines HER2 targeting with precision payload - BioWorld MedTech
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing - The Globe and Mail
Transcript : HUTCHMED Limited Presents at Deutsche Bank ADR Virtual Investor Conference 2025, Nov-04-2025 08 - MarketScreener
HUTCHMED (China) Limited (HCM) HUTCHMED (China) Limited Presents at Deutsche Bank ADR Virtual Investor Conference 2025Slideshow (NASDAQ:HCM) 2025-11-04 - Seeking Alpha
Hutchmed Strengthens Position Within FTSE AIM 100 Index Healthcare Sphere - Kalkine Media
HUTCHMED Announces Enrollment Completed of SAFFRON Global - GlobeNewswire
Hutchmed takes wraps off expanding oncology pipeline - Sharecast.com
Market news - investments.halifax.co.uk
RCSHutchmed China LtdUpdates from R&D Event - TradingView
HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event - The Manila Times
ETFs Investing in HUTCHMED (China) Limited Sponsored ADR Stocks - TradingView
CORRECTION -- International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025 - The Manila Times
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025 - Macau Business
International companies to host live webcasts at Deutsche - GlobeNewswire
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives Average Rating of "Hold" from Brokerages - MarketBeat
Vanguard Personalized Indexing Management LLC Buys 4,773 Shares of Cleanspark, Inc. $CLSK - Defense World
Vanguard Personalized Indexing Management LLC Sells 354 Shares of Cathay General Bancorp $CATY - Defense World
Hutchmed upbeat on preclinical data for novel cancer therapy - Sharecast.com
HUTCHMED Highlights HMPL-A251 Data Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - The Manila Times
HUTCHMED Highlights HMPL-A251 Data Presented at the - GlobeNewswire
Allianz Asset Management GmbH Sells 80,000 Shares of HUTCHMED (China) Limited Sponsored ADR $HCM - MarketBeat
Finanzdaten der Hutchmed China Limited Adr-Aktie (HCM)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.03%
2.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):